116 results
Page 4 of 6
8-K
EX-99.1
69tkgkkhqbkaxsln
3 Aug 20
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
6:58am
8-K
EX-99.1
ncudq
8 May 20
Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
7:30am
8-K
EX-10.2
8wj ttucxagg8rr1
20 Apr 20
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
ufurn 2csfdgsg2c7os
16 Mar 20
Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
4:08pm
8-K
EX-99.1
8nqsuy
7 Nov 19
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
4:15pm
8-K
c0ueraxm76a7emmy
15 Oct 19
Departure of Directors or Certain Officers
7:00am
8-K
EX-99.3
58dgkkdzt pi0uprk
5 Sep 19
Departure of Directors or Certain Officers
4:07pm
8-K
EX-99.1
nynpcm94vq 2n3zuu
8 Aug 19
Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity
8:16am
8-K
nh1x4etc dq
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-10.1
u0rv8876 1vxmfjqn
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-99.1
9k5bdqn 6g957cl5
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-10.1
jfzp6k f9yu9pzy0r
17 Jul 19
Entry into a Material Definitive Agreement
7:31am
8-K
EX-99.4
e9796k
21 Jun 19
Other Events
8:24am
8-K
EX-99.3
quwije
21 Jun 19
Other Events
8:24am
425
klik0czvvkai7pn
14 Mar 19
Business combination disclosure
4:02pm